TrypZean®

Purchasing

Now selling direct to customers. Choose a pack size below and complete the form to buy from us and save!

Discounted rates are available for orders over 1 gram.

For quantities less than 25mg, visit Millipore Sigma (Product No. T3568).

TrypZean®

Recombinant bovine trypsin , expressed in maize, lyophilized powder, ≥3,350 units/mg solid (USP)

About TrypZean®

Produced in a plant-based recombinant system, TrypZean® delivers equivalent performance to native pancreatic trypsin sourced from bovine tissue- without the regulatory, ethical, or contamination concerns associated with animal-derived materials.

Because it is animal-origin-free, TrypZean® eliminates the risks of adventitious agents and variability inherent to traditional sources. This makes it exceptionally well suited for processes that must meet the most stringent safety expectations in biologics and biopharmaceutical manufacturing, including cell culture, vaccine production, and downstream purification.

With TrypZean®, manufacturers gain high activity, high purity, reliable consistency, and simplified regulatory compliance— all in a cleaner, safer, and fully traceable supply chain.

TrypZean® provides the following advantages:

  • Certified animal-free, TrypZean® eliminates the risk of animal-source contaminants such as viruses and bovine spongiform encephalopathy (BSE).

  • TrypZean® is free of contaminants associated with animal source trypsin and may be used in lower concentrations in some applications.

Commercial applications include:

  • Cell culture: Dissociation of attachment–dependent cell lines from plasticware in serum-free and serum-supplemented systems

  • Insulin manufacture: Cleaves “C” peptide from proinsulin to form active insulin

  • Vaccine manufacture: Cleaves undesirable antigens from cells in both human and veterinary vaccine manufacture

Certificate of Analysis:

References:

Jozef, Barbara, et al. "A systematic approach towards long-term, serum-free cultivation of fish cells with the RTgill-W1 cell line as example." NAM Journal 1 (2025): 100008.

Wang, Li, et al. "Development of pre-pandemic influenza candidate vaccine viruses for use in vaccine manufacturing." npj Vaccines (2026).Zhang, Longteng, et al. "Gelation and emulsification profiles of different commercial soy protein isolates: A proteomic insight through globulin subunit compositions and oxidative modifications." Food Hydrocolloids 164 (2025): 111173.

Zielen, Amanda Colvin, et al. "Ultrasound-Guided Rete Testis Approach to Sperm Aspiration and Spermatogonial Stem Cell Transplantation in Patients with Azoospermia." medRxiv (2025): 2025-03.

Caruso, Alayna C., et al. "Targeting intracellular tau with a gene-encoded single-chain antibody promotes neuronal homeostasis and ameliorates tau pathology." bioRxiv (2025): 2025-08.

Finney, Caitlin, et al. "Cross-tissue immune profiling of APOE ε4 reveals early dysregulation in Alzheimer’s disease." Research Square (2025): rs-3.

Hunt, Jason, et al. "Upscaling manufacturing of human induced pluripotent-derived mesenchymal stromal cells in a 1-l bioreactor system." Osteoarthritis and Cartilage 31 (2023): S229.

Waqar, Khadija, et al. "Covalent bonding of 4-methylcatechol to β-lactoglobulin results in the release of cysteine-4-methylcatechol adducts after in vitro digestion." Food Chemistry 397 (2022): 133775.

Harada, Yuichi, et al. "Evaluation of a qualified MDCK cell line for virus isolation to develop cell-based influenza vaccine viruses with appropriate antigenicity." Vaccine 42.23 (2024): 126242.

Legal information

TrypZean® is a registered trademark of ProdiGene, Inc.